33 reports

  • ALLERGIC RHINITIS IMMUNOTHERAPY: KEY METRICS IN THE 7MM
  • SALES FORECAST BY COMPANY FOR ALLERGIC RHINITIS IMMUNOTHERAPY IN THE 5EU IN 2018 AND

This means [if] a patient is sensitive toward birch and grass [they] will receive two specific immunotherapies, one with birch and one with grass.

  • Immunotherapy
  • Japan
  • Demand
  • Shionogi & Co., Ltd.
  • Torii Pharmaceutical Co., Ltd.
  • 7.4 EXTENDING THE USE OF IMMUNOTHERAPIES TO THE MSS POPULATION
  • JAPAN CRC MARKET - DRIVERS AND BARRIERS, 2016

US KEY OPINION LEADER CURRENTLY, THERE IS ONLY ONE LATE-STAGE IMMUNOTHERAPY IN THE PIPELINE THAT TARGETS MSS PATIENTS, ROCHE' S TECENTRIQ.

  • Immunotherapy
  • Japan
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

N. (2016) ' UPDATE ON PSORIASIS IMMUNOPATHOGENESIS AND TARGETED IMMUNOTHERAPY', SEMINARS IN IMMUNOPATHOLOGY, PP. ##-##.

  • Immunotherapy
  • Japan
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • SOURCES

Classification of current anticancer immunotherapies.

  • Immunotherapy
  • Japan
  • United States
  • Celgene Corporation
  • Novartis AG

Randomized phase II/ III trial of active immunotherapy with OPT-##/ OPT- ## in patients with metastatic breast cancer.

  • Immunotherapy
  • East Asia
  • Japan
  • Pfizer Inc.
  • Roche Group

Journal for ImmunoTherapy of Cancer; ##:##.

  • Immunotherapy
  • Japan
  • United States
  • Novartis AG
  • Pfizer Inc.

Studies suggest CD## CAR-T cell-based immunotherapies effectively recognize and kill CD##-positive target cells and result in a high clinical response rate in the treatment of refractory B-cell malignancies, including DLBCL.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Japan

Yescarta

8770 10000 7800

Studies suggest a high clinical response rate of CD## CAR-T cell-based immunotherapy in the treatment of refractory B-cell malignancies.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Japan
  • Proportion of bulky stage mantle cell lymphoma patients receiving aggressive first-line/induction therapy, by country, 2016
  • REGIMENS OF RITUXIMAB PLUS CHOP OR BENDAMUSTINE ARE THE MAINSTAY OF LESS AGGRESSIVE INDUCTION THERAPIES

Kite Pharma press release (2012) Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products.

  • Immunotherapy
  • Japan
  • Celgene Corporation
  • Pfizer Inc.
  • Roche Group

Lancet Oncology, ##(##), ##-##.

  • Immunotherapy
  • Japan
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.

NHL: Follicular lymphoma Disease Coverage | Forecast: Follicular Lymphoma DMKC## US ## ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ##

  • Immunotherapy
  • Japan
  • Biogen Idec Inc.
  • Gilead Sciences, Inc.
  • Roche Group

PLoS One, ##(##), e##.

  • Immunotherapy
  • Lymphoma
  • Japan
  • Celgene Corporation
  • Roche Group
  • ATEZOLIZUMAB DRUG PROFILE
  • PD-1/PD-L1 INHIBITOR CLASS SALES IN TNBC ACROSS THE US, JAPAN, AND FIVE MAJOR EU MARKETS, 2015-24

Atezolizumab will be the first immunotherapy available for TNBC patients in the firstline setting.

  • Immunotherapy
  • Japan
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • TESARO, Inc.

Gastric cancer

4385 5000 3900

Raufi AG, Klempner SJ (2015) Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

  • Immunotherapy
  • Japan
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Clinical Trial profile. 141 Trial Title
  • Clinical Trial profile. 616 Trial Title

Part ## - Proteomics Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy
  • Clinical Trial
  • Immunotherapy
  • Pharmaceutical
  • Japan
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE
  • STG-120 - DRUG PROFILE

The molecules developed by Companies in Phase III, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Allergy
  • Immunotherapy
  • Medical Biotechnology
  • Japan
  • Product Initiative
  • ALK-ABELLO RAISES USD101.5 MILLION IN PRIVATE PLACEMENT OF B SHARES
  • ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares

When adjusted for one-off milestone payments and acquisitions, revenue decreased by ##% organically.

  • Immunotherapy
  • Japan
  • North America
  • Company Financials
  • ALK-Abelló Group

Alzheimer's disease

4385 5000 3900
  • Executive Summary

BIBLIOGRAPHY Alzheimer' s disease Disease Coverage | Forecast: Alzheimer' s Disease DMKC## US ##, ## ## ## ## ## ## ## ## ## ## -##. ## Japan ## ## ## ## ## ## ## ## ## ## -##. ## France ## ## ## ## ## ## ## ## ## ## -##. ## German

  • Immunotherapy
  • Japan
  • Eli Lilly & Co.
  • Lundbeck Inc.
  • Roche Group

ACCORDING TO GSK, PATENTS IN RELATION TO THE ANTIBODY TECHNOLOGY THAT BINDS TO BLYS FOR BENLYSTA, WHICH WERE CHALLENGED BY ELI LILLY, HAVE BEEN RESOLVED.

  • Immunotherapy
  • Japan
  • Mitsubishi Corporation
  • Remicade group
  • Roche Group
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE
  • STG-120 - DRUG PROFILE

The drug or placebo was given for eight weeks before oral immunotherapy began, and also for the first eight weeks of oral immunotherapy.

  • Allergy
  • Immunotherapy
  • Therapy
  • Japan
  • Product Initiative
  • Clinical Trial profile. 529 Trial Title
  • Clinical Trial profile. 904 Trial Title

Part ## - Proteomics Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy
  • Clinical Trial
  • Immunotherapy
  • Pharmaceutical
  • Japan
  • Official Title
  • Clinical Trial profile. 77 Trial Title

## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ASIT Biotech SA ## ## ## ## ## ## ## ## Anergis SA ## ## ## ## ## ## ## ## Allied Researc

  • Clinical Trial
  • Immunotherapy
  • Pharmaceutical
  • Japan
  • Allergy Therapeutics plc
  • Nov 07, 2017: Osaka University: New Strategy for Multiple Myeloma Immunotherapy

Nov ##, 2017: Osaka University: New Strategy for Multiple Myeloma Immunotherapy In recent decades monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both solid tumors and blood cancers.

  • Healthcare
  • Immunotherapy
  • Pharmaceutical
  • Japan
  • Mitsubishi Corporation

Txcell SA (Txcell) is a biotechnology company that develops and innovates cell-based immunotherapy utilizing antigen specific regulatory T-cells.

  • Immunotherapy
  • Medical Biotechnology
  • Japan
  • Product Initiative
  • Astellas Pharma Inc.

GlobalData AnGes Inc reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Immunotherapy
  • Polyclonal Antibody
  • Japan
  • Company
  • AnGes MG, Inc.

Article ##.

  • Hospital
  • Immunotherapy
  • Pharmaceutical
  • Japan
  • Kyowa Hakko Kirin Co., Ltd.
  • VACCINE FOR ONCOLOGY - DRUG PROFILE

ABSTRACT ##: DSP-##, A NOVEL COCKTAIL DESIGN OF WT## PEPTIDE VACCINE, AND ITS COMBINATIONAL IMMUNOTHERAPY WITH IMMUNE CHECKPOINT-BLOCKING ANTIBODY AGAINST PD-## GOTO M##, NAKAMURA M##, SUGINOBE N##, TAKASU H##, TAKANASHI Y##, BAN H##, LI CJ## ##.

  • Hospital
  • Immunotherapy
  • Vaccine
  • Japan
  • Product Initiative

GlobalData AnGes Inc reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Immunotherapy
  • Polyclonal Antibody
  • Japan
  • Company
  • AnGes MG, Inc.

Zevalin

8770 10000 7800

However, Zevalin has not gained significant uptake in this market due to logistical and economic issues associated with its administration, and it continues to be at a disadvantage compared to the more convenient targeted immunotherapies in FL.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Japan
  • Litigation And Patent

Humira was originally developed by Cambridge Antibody Technologies, and was subsequently licensed to Abbott (now AbbVie).

  • Immunotherapy
  • Japan
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • TiGenix NV